RXRX · Recursion Pharmaceuticals, Inc. · Documents
$3.64
-0.03 (-0.68%)
At close · Oct 21
Return incl. dividend (before tax)
Market Cap
$1.96B
Shares
535.34M
Volume · Oct 21
4.11M
Avg daily vol (3M)
21.64M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Recursion Pharmaceuticals priced 61,540,000 shares at $3.25, expects approximately $200 million gross proceeds, and expects its cash runway to extend into 2029. Sanofi optioned a development candidate, triggering a $10 million milestone payment. | 2026-10-15 | — | |
| 8-K | — | 2026-09-21 | 2026-09-15 | |
| Investor Event Transcript | — | 2026-09-15 | 2026-09-30 | |
| 10-Q | — | 2026-08-05 | 2026-06-30 | |
| 8-K | — | 2026-08-05 | — | |
| 8-K | — | 2026-06-18 | 2026-06-17 | |
| Investor Event Transcript | — | 2026-06-09 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-05-12 | 2026-06-30 | |
| 10-Q | — | 2026-05-06 | 2026-03-31 | |
| 8-K | — | 2026-05-06 | — | |
| DEFA14A | — | 2026-04-30 | — | |
| 8-K | — | 2026-04-30 | 2026-04-28 | |
| DEF 14A | — | 2026-04-30 | — | |
| 8-K | — | 2026-03-25 | — | |
| 8-K | — | 2026-02-25 | — | |
| 10-K | — | 2026-02-25 | 2025-12-31 | |
| 8-K | — | 2026-01-12 | — | |
| 8-K | — | 2025-12-08 | — | |
| 8-K | — | 2025-11-26 | — | |
| 8-K | — | 2025-11-05 | 2025-11-04 | |
| 10-Q | — | 2025-11-05 | 2025-09-30 | |
| 8-K | — | 2025-10-29 | — | |
| 8-K/A | — | 2025-08-29 | 2025-07-08 | |
| 8-K | — | 2025-08-05 | — | |
| 10-Q | — | 2025-08-05 | 2025-06-30 | |
| 8-K | — | 2025-07-08 | — | |
| 8-K | — | 2025-06-18 | — | |
| 8-K | — | 2025-06-10 | — | |
| 8-K | — | 2025-05-09 | — | |
| 8-K | — | 2025-05-05 | — | |
| 10-Q | — | 2025-05-05 | 2025-03-31 | |
| DEFA14A | — | 2025-04-28 | — | |
| DEF 14A | — | 2025-04-28 | — | |
| 8-K | — | 2025-03-18 | 2025-03-15 | |
| 10-K | — | 2025-02-28 | 2024-12-31 | |
| 8-K | — | 2025-02-28 | — | |
| S-3ASR | — | 2025-02-12 | — | |
| 8-K | — | 2025-01-13 | — | |
| 8-K | — | 2024-12-17 | — | |
| 8-K | — | 2024-12-03 | 2024-12-02 | |
| 8-K/A | — | 2024-11-27 | 2024-11-19 | |
| 8-K/A | — | 2024-11-26 | 2024-08-08 | |
| 8-K | — | 2024-11-20 | 2024-11-19 | |
| 8-K | — | 2024-11-13 | 2024-11-12 | |
| 8-K | — | 2024-11-13 | — | |
| DEFA14A | — | 2024-11-06 | — | |
| 8-K | — | 2024-11-06 | — | |
| 8-K | — | 2024-11-06 | 2024-11-05 | |
| 10-Q | — | 2024-11-06 | 2024-09-30 | |
| DEFA14A | — | 2024-10-30 | — |
Showing 1–50 of 140 filings
Key facts
CIK
1601830
CUSIP
75629V104
13F (30d)
39 filings
39 filers
Visit website
Investor relations